These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25600203)

  • 21. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
    Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
    Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
    Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
    William AD; Lee AC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Tan E; Chen D; Williams M; Sun ET; Goh KC; Ong WC; Goh SK; Hart S; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
    J Med Chem; 2011 Jul; 54(13):4638-58. PubMed ID: 21604762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolism of aildenafil in vivo in rats and in vitro in mouse, rat, dog, and human liver microsomes.
    Li Y; Wu L; Gu Y; Si D; Liu C
    Drug Test Anal; 2014 Jun; 6(6):552-62. PubMed ID: 24311535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor.
    Rioux N; Duncan KW; Lantz RJ; Miao X; Chan-Penebre E; Moyer MP; Munchhof MJ; Copeland RA; Chesworth R; Waters NJ
    Xenobiotica; 2016; 46(3):268-77. PubMed ID: 26294260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics.
    Gu Y; Wang J; Li K; Zhang L; Ren H; Guo L; Sai Y; Zhang W; Su W
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):95-115. PubMed ID: 24817647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
    Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
    Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation.
    Ye Q; Jiang M; Huang WT; Ling Y; Olson SH; Sun D; Xu G; Yan X; Wong BK; Jin L
    Xenobiotica; 2015; 45(8):681-92. PubMed ID: 25798742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
    Younes A; Romaguera J; Fanale M; McLaughlin P; Hagemeister F; Copeland A; Neelapu S; Kwak L; Shah J; de Castro Faria S; Hart S; Wood J; Jayaraman R; Ethirajulu K; Zhu J
    J Clin Oncol; 2012 Nov; 30(33):4161-7. PubMed ID: 22965964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis.
    Huang Z; Li H; Zhang Q; Tan X; Lu F; Liu H; Li S
    Drug Des Devel Ther; 2015; 9():4319-28. PubMed ID: 26273193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The identification of lobeglitazone metabolites in rat liver microsomes and the kinetics of the in vivo formation of the major metabolite M1 in rats.
    Lee JH; Ahn SH; Maeng HJ; Lee W; Kim DD; Chung SJ
    J Pharm Biomed Anal; 2015 Nov; 115():375-82. PubMed ID: 26275726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro.
    Gerisch M; Heinig R; Engelen A; Lang D; Kolkhof P; Radtke M; Platzek J; Lovis K; Rohde G; Schwarz T
    Drug Metab Dispos; 2018 Nov; 46(11):1546-1555. PubMed ID: 30171161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs.
    Zhang D; Raghavan N; Chen SY; Zhang H; Quan M; Lecureux L; Patrone LM; Lam PY; Bonacorsi SJ; Knabb RM; Skiles GL; He K
    Drug Metab Dispos; 2008 Feb; 36(2):303-15. PubMed ID: 17984286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.
    Podoll T; Pearson PG; Evarts J; Ingallinera T; Bibikova E; Sun H; Gohdes M; Cardinal K; Sanghvi M; Slatter JG
    Drug Metab Dispos; 2019 Feb; 47(2):145-154. PubMed ID: 30442651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
    Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans.
    Atsriku C; Hoffmann M; Ye Y; Kumar G; Surapaneni S
    Xenobiotica; 2015 May; 45(5):428-41. PubMed ID: 25482583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
    Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro studies on the oxidative metabolism of 20(s)-ginsenoside Rh2 in human, monkey, dog, rat, and mouse liver microsomes, and human liver s9.
    Li L; Chen X; Zhou J; Zhong D
    Drug Metab Dispos; 2012 Oct; 40(10):2041-53. PubMed ID: 22829543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.